Contact

What are you looking for?

Nitrosamine Control: Understanding the New FDA and EMA Regulations

November 14, 2021
Download now

After their detection in 2018, nitrosamines have been a pressing topic in the pharmaceutical world.

With major regulatory updates introduced by the FDA and EMA, all pharmaceutical manufacturers have been instructed to conduct a risk assessment and proactively test their products for the presence of nitrosamines. It’s therefore crucial for pharmaceutical companies and manufacturers to get up to speed with these latest requirements.

In this technical bulletin, we provide more details on the three-step risk assessment proposed to comply with FDA & EMA methods.

Nitrosamine Control: Understanding the New FDA and EMA Regulations

Related White Papers

News & Insights

  • SGS Health Science Services

1 Place des Alpes,

P.O. Box 2152,

1211, Geneva, Switzerland